Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824855 | 0.90 | MAPT (0.44) | KDRMEN1KMT2APDE2ARXFP1 | |
| SCHEMBL496930 | 0.88 | PDE2A (0.51) | PDE2ARXFP1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL2828064 | 0.85 | PDE2A (0.51) | KDRMEN1KMT2APDE2ARXFP1 | |
| SCHEMBL2824919 | 0.84 | KDR (0.64) | KDRMEN1KMT2ARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2828806 | 0.83 | KDR (0.63) | KDRMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL496593 | 0.82 | PDE2A (0.46) | PDE2ARXFP1ALDH1A1HPGDTHRB | |
| SCHEMBL2823870 | 0.82 | PDE2A (0.46) | KDRMEN1KMT2APDE2ARXFP1 | |
| SCHEMBL496760 | 0.81 | RXFP1 (0.46) | KDRPDE2ARXFP1ALDH1A1HPGD | |
| SCHEMBL2826130 | 0.77 | MAPT (0.46) | KDRPDE2ARXFP1POLB | |
| SCHEMBL2830725 | 0.77 | MAPT (0.52) | KDRMEN1KMT2ARXFP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| EP-1791543-B1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1791543-A2 | TRIAZOLOPHTHALAZINES | Altana Pharma AG (DE) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006024640-A2 | TRIAZOLOPHTHALAZINES | ALTANA PHARMA AG (DE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | KDR 1654/4885MEN1 2920/4885KMT2A 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.